Nootropil (Piracetam 1200 mg)
Film-coated tablet containing piracetam — a nootropic agent used in cortical myoclonus and select cognitive disorders
Quick Facts About Nootropil
Key Takeaways About Nootropil
- Primary approved indication: Symptomatic treatment of cortical myoclonus in adults, used alone or in combination with other anti-myoclonic therapies
- Renal excretion is critical: Approximately 80–100% of piracetam is eliminated unchanged by the kidneys, requiring dose adjustment in renal impairment and contraindication in severe renal failure
- Never stop abruptly: Sudden discontinuation in myoclonus patients may trigger breakthrough myoclonus or generalised seizures; always taper gradually under medical supervision
- Bleeding risk awareness: Piracetam has antiplatelet properties and may increase bleeding risk when combined with anticoagulants or antiplatelet agents
- Not FDA-approved: Nootropil is not approved by the U.S. Food and Drug Administration; availability and indications vary significantly between countries
What Is Nootropil and What Is It Used For?
Nootropil is the original brand name for piracetam, a prescription nootropic medication used primarily for the symptomatic treatment of cortical myoclonus in adults. In some countries it is also prescribed as adjunctive therapy for cognitive disorders associated with cerebrovascular disease, age-related cognitive decline, and breakthrough dyslexia in children.
Nootropil contains the active substance piracetam, a synthetic cyclic derivative of gamma-aminobutyric acid (GABA). Piracetam was first synthesised in 1964 by the Belgian pharmaceutical company UCB Pharma and became the prototype compound of the nootropic drug class — a term coined in 1972 by the Romanian psychologist and chemist Corneliu Giurgea to describe agents that enhance cognition without the typical side effects of psychostimulants or sedatives. Over five decades of clinical use have made piracetam one of the most extensively studied compounds in clinical pharmacology, with thousands of peer-reviewed publications describing its pharmacological properties and therapeutic applications.
The 1200 mg film-coated tablet formulation is designed for oral administration and is intended to be swallowed whole with a glass of water. The higher 1200 mg strength is particularly useful for patients requiring large daily doses, as Nootropil is typically prescribed in gram quantities rather than milligram quantities. The film coating protects the active ingredient from degradation, facilitates swallowing, and may help mask any inherent taste characteristics of the compound. Unlike many neurological medications, piracetam does not bind to specific receptors but rather exerts its effects through membrane-based mechanisms and subtle modulation of neurotransmission.
The approved indications for Nootropil vary by country and regulatory jurisdiction. In the European Union and the United Kingdom, the primary approved indication is the symptomatic treatment of cortical myoclonus in adults, either as monotherapy or in combination with other anti-myoclonic treatments. Cortical myoclonus is a neurological condition characterised by brief, involuntary muscle jerks that originate from the cerebral cortex and can be highly disabling. In several European countries, Nootropil is also licensed for the treatment of cognitive impairment in elderly patients, certain types of vertigo, and – notably – as an adjunctive treatment for dyslexia in children from 8 years of age, used alongside standard educational and speech therapy interventions.
Piracetam is not approved by the U.S. Food and Drug Administration (FDA) and is not available as a prescription medicine in the United States. In countries where Nootropil is available, it is classified as a prescription-only medication because safe and effective use requires medical evaluation, appropriate patient selection, dose titration, and monitoring for potential adverse effects and drug interactions. Despite widespread availability of piracetam as an unregulated supplement on the internet for purported "cognitive enhancement," such off-label use is not supported by robust clinical evidence in healthy individuals and is not recommended.
The term "nootropic" (from Greek nous = mind, tropein = to turn) was introduced by Corneliu Giurgea in 1972 to describe compounds that enhance learning and memory, protect the brain against various physical or chemical injuries, enhance resistance to cerebral hypoxia, and exhibit very low toxicity. Piracetam was the prototypical compound meeting all of Giurgea's original criteria and remains the reference standard for this pharmacological class.
How Does Piracetam Work?
The precise mechanisms by which piracetam exerts its therapeutic effects are not fully understood, but decades of research have identified several complementary pharmacological actions. Unlike conventional psychotropic drugs, piracetam does not bind to specific neurotransmitter receptors and does not produce sedation, stimulation, or alterations in mood at therapeutic doses. Instead, it appears to modulate neuronal function through membrane-level effects and haemorheological actions.
At the neuronal membrane level, piracetam interacts with phospholipids and membrane proteins, improving membrane fluidity and potentially restoring normal function in membranes that have been damaged by ageing, ischaemia, or other pathological processes. Electrophysiological studies have demonstrated that piracetam enhances glutamatergic neurotransmission at AMPA receptors and modulates the release of acetylcholine and other neurotransmitters. These actions may underlie its beneficial effects on cognitive function in certain pathological states.
Piracetam also exhibits well-documented haemorheological effects, meaning it improves the flow properties of blood. It reduces the aggregation of platelets and erythrocytes, decreases the rigidity of red blood cells, and improves microcirculation in the brain and peripheral tissues. These effects may contribute to its therapeutic benefit in conditions involving impaired cerebral blood flow and explain the observed antiplatelet activity that can occasionally manifest as an increased bleeding tendency.
What Should You Know Before Taking Nootropil?
Before starting Nootropil, inform your doctor about all medical conditions, particularly kidney disease, bleeding disorders, cerebral haemorrhage, or Huntington's disease, as well as any medications you take, including anticoagulants and antiplatelet agents. Your doctor will evaluate whether Nootropil is safe and appropriate for you and adjust the dose based on kidney function.
Contraindications
Nootropil is contraindicated and must not be used in the following situations. Taking Nootropil when any of these conditions apply may result in serious harm, ineffective treatment, or unnecessary exposure to adverse effects.
Do not take Nootropil if you have a known hypersensitivity to piracetam, to other pyrrolidone derivatives such as levetiracetam or brivaracetam, or to any of the excipients listed in the patient information leaflet. Symptoms of hypersensitivity may include skin rash, itching, urticaria, angioedema (swelling of the face, lips, tongue, or throat), or, rarely, anaphylaxis. If you experience any such reaction, stop taking Nootropil and seek immediate medical attention.
Nootropil is contraindicated in patients with severe renal impairment, defined as a creatinine clearance below 20 mL/min. Because piracetam is eliminated almost exclusively by renal excretion in unchanged form, severely reduced kidney function leads to drug accumulation and an increased risk of adverse effects. Patients with less severe renal impairment require dose adjustment rather than absolute contraindication. Your doctor will assess your kidney function before prescribing Nootropil and may order periodic blood tests to monitor renal function during treatment.
Nootropil must not be used in patients with cerebral haemorrhage. Because of its antiplatelet properties, piracetam could worsen bleeding or impair haemostasis in patients with an acute bleed in the brain. It is also contraindicated in patients with Huntington's disease, a progressive neurodegenerative disorder, because piracetam has been reported to exacerbate involuntary movements (chorea) in affected individuals.
Warnings and Precautions
Talk to your doctor or pharmacist before taking Nootropil if you have any of the following conditions or circumstances. These situations may require special monitoring, dose adjustment, or careful risk-benefit assessment before initiating therapy.
- Mild or moderate renal impairment: Dose reduction is required in patients with creatinine clearance between 20 and 80 mL/min. Your doctor will calculate the appropriate dose based on your estimated glomerular filtration rate (eGFR)
- Haemostatic disorders: Patients with disorders of haemostasis or major surgery should be managed with caution due to piracetam's antiplatelet effects; your surgeon may recommend discontinuing Nootropil before planned surgical procedures
- Severe haemorrhage or risk of bleeding: Use caution in patients with conditions predisposing to bleeding, including gastrointestinal ulceration or a history of stroke due to haemorrhage
- Elderly patients: Older adults often have reduced renal function and may require lower doses; regular monitoring of creatinine clearance is recommended for long-term treatment
- Patients with epilepsy: Close monitoring is advised because abrupt dose changes can affect seizure threshold in some individuals
Regular medical follow-up is recommended while taking Nootropil to assess the effectiveness of treatment and to detect any potential adverse effects early. Your doctor may order periodic blood tests to monitor kidney function, coagulation parameters, and liver function. In patients with cortical myoclonus, treatment response should be reassessed regularly, and dose titration should be performed cautiously to find the lowest effective dose.
Nootropil is not intended to treat conditions other than those for which it has been prescribed by your physician. Do not use Nootropil for self-treatment of perceived cognitive complaints, exam preparation, or general "brain boosting" purposes. The use of piracetam as a cognitive enhancer in healthy individuals is not supported by adequate clinical evidence, and unsupervised use may expose you to unnecessary risk without demonstrated benefit.
Pregnancy and Breastfeeding
There are insufficient data on the use of Nootropil in pregnant women. Animal reproduction studies have not shown direct or indirect harmful effects with respect to pregnancy, embryonic or foetal development, parturition, or postnatal development. However, as a precautionary measure, Nootropil should not be used during pregnancy unless clearly necessary after careful evaluation of the potential benefits and risks by your prescribing physician. Women of childbearing potential should use effective contraception while taking Nootropil if pregnancy would be problematic.
Piracetam is excreted into human breast milk, with milk concentrations reaching levels similar to those found in maternal plasma. For this reason, the use of Nootropil while breastfeeding is generally not recommended. A decision should be made either to discontinue breastfeeding or to discontinue Nootropil therapy, taking into account the importance of the medication for the mother's health and the potential risks to the breastfed infant. Discuss this decision carefully with your obstetrician, paediatrician, or prescribing physician.
If you become pregnant while taking Nootropil, inform your doctor as soon as possible. Do not stop taking Nootropil abruptly, particularly if you are being treated for cortical myoclonus, as sudden discontinuation may precipitate breakthrough myoclonus or seizures. Your doctor will help you decide on the safest course of action, which may involve gradual dose reduction, switching to an alternative medication, or continuing treatment if the clinical situation justifies it.
Do not stop taking Nootropil suddenly, especially if you are being treated for cortical myoclonus. Sudden discontinuation may precipitate breakthrough myoclonic symptoms or generalised seizures. Any treatment change must be made gradually under medical supervision, typically by reducing the dose by 1.2 grams every two days until complete withdrawal.
Effects on Driving and Operating Machinery
In view of potential side effects reported with piracetam, such as somnolence, drowsiness, vertigo, or agitation, caution should be exercised when driving a vehicle or operating machinery. Patients should assess their individual response to Nootropil before engaging in activities requiring full mental alertness and motor coordination. If you experience any of these effects, do not drive or operate heavy equipment until the effects have fully resolved. Discuss any concerns about driving safety with your doctor.
How Does Nootropil Interact with Other Drugs?
Nootropil may interact with thyroid hormones (causing confusion and irritability), anticoagulants such as warfarin (potentiating bleeding risk), and other medications affecting the central nervous system. Always provide your doctor and pharmacist with a complete list of all medications, supplements, and herbal remedies you take.
Drug interactions can occur through pharmacokinetic mechanisms (affecting how a drug is absorbed, distributed, metabolised, or excreted) or pharmacodynamic mechanisms (affecting how drugs act together at their sites of action). Piracetam has a relatively favourable drug interaction profile because it is not metabolised by cytochrome P450 enzymes and is not highly protein-bound. However, several clinically relevant interactions have been documented and require attention during concomitant use.
Because piracetam is eliminated almost exclusively unchanged by the kidneys, drugs that alter renal function or compete for renal tubular secretion may affect its elimination. Conversely, piracetam is unlikely to cause significant pharmacokinetic interactions through hepatic enzyme induction or inhibition. The most clinically important interactions are pharmacodynamic, resulting from additive or synergistic effects on haemostasis, the central nervous system, or endocrine function.
Special caution is required when piracetam is combined with anticoagulant or antiplatelet therapy due to its own effects on platelet aggregation. Clinical studies have shown that high doses of piracetam (9.6 grams per day) can prolong bleeding time and may potentiate the antiplatelet effects of aspirin. When used in patients already receiving warfarin, piracetam has been reported to increase prothrombin time, although the clinical significance of this interaction is variable.
Documented Drug Interactions
| Drug / Drug Class | Type of Interaction | Clinical Significance | Recommendation |
|---|---|---|---|
| Thyroid extract (T3/T4) | Pharmacodynamic | Reports of confusion, irritability, and sleep disturbances when piracetam is combined with thyroid hormone | Use with caution; monitor for neuropsychiatric symptoms |
| Warfarin | Pharmacodynamic | May increase prothrombin time and INR, potentially increasing bleeding risk | Monitor INR more frequently; adjust warfarin dose as needed |
| Antiplatelet agents (aspirin, clopidogrel) | Pharmacodynamic (additive) | Enhanced antiplatelet effect; increased risk of bleeding, particularly with high piracetam doses | Monitor for signs of bleeding; consider dose adjustment |
| Direct oral anticoagulants (DOACs) | Pharmacodynamic (theoretical) | Potential additive bleeding risk; clinical data limited | Use with caution; monitor for bleeding symptoms |
| Carbamazepine | No significant pharmacokinetic interaction | Piracetam does not affect carbamazepine plasma levels; safe combination in myoclonus therapy | No dose adjustment typically needed |
| Antiepileptic drugs | Pharmacodynamic (potentially beneficial) | Often used in combination for cortical myoclonus (e.g., with valproate, clonazepam, levetiracetam) | Combination is a standard therapeutic approach under specialist supervision |
| Alcohol | Minimal pharmacokinetic interaction | Piracetam does not significantly alter blood alcohol levels; no acute interaction demonstrated | Moderate alcohol consumption as advised by physician |
The table above lists the most clinically significant interactions but is not exhaustive. Many other medications may theoretically interact with piracetam, and new interactions may be identified as clinical experience accumulates. Always carry an up-to-date list of all your medications (including over-the-counter products, vitamins, dietary supplements, and herbal remedies) and share it with every healthcare provider you visit. This practice is especially important before surgery, dental procedures, or initiation of any new medication.
Nootropil tablets can be taken with or without food. Food may slightly delay the rate but not the extent of piracetam absorption, and this interaction is not clinically significant. There is no specific requirement to avoid particular foods or beverages during treatment, although moderation in alcohol consumption is generally advised as a sensible precaution.
What Is the Correct Dosage of Nootropil?
The standard Nootropil 1200 mg tablet is taken orally with or without food. For cortical myoclonus in adults, the usual starting dose is 7.2 grams per day divided into two or three doses, titrated upward by 4.8 grams every three to four days up to a maximum of 24 grams per day. Dose reduction is required in renal impairment.
The correct dose of Nootropil depends on the indication being treated, the severity of symptoms, the patient's age, body weight, and — critically — renal function. Piracetam is eliminated almost exclusively by the kidneys in unchanged form, so dose adjustment based on creatinine clearance is essential to prevent accumulation and minimise the risk of adverse effects. Your doctor will determine the most appropriate starting dose and titration schedule based on your individual circumstances.
Nootropil is usually taken with or without food, with a glass of water. The tablets should be swallowed whole and not crushed or chewed, as this may affect the film coating's protective function. If your daily dose is divided into multiple administrations, try to space the doses evenly throughout the day (for example, morning, midday, and evening) to maintain stable plasma levels. It is helpful to take the medication at the same times each day to establish a consistent routine and reduce the likelihood of missed doses.
Adults – Cortical Myoclonus
Standard Adult Dosage for Cortical Myoclonus
The recommended starting dose for cortical myoclonus in adults is 7.2 grams per day, divided into two or three doses. Using the 1200 mg film-coated tablets, this corresponds to six tablets daily (for example, two tablets in the morning, two at midday, and two in the evening; or three tablets twice daily).
Depending on clinical response, the dose should be increased by 4.8 grams per day every three to four days until improvement is observed or up to a maximum daily dose of 24 grams (twenty tablets of 1200 mg), divided into two or three administrations. The minimum effective dose should be used to maintain symptom control.
Treatment with other anti-myoclonic medications (such as sodium valproate, clonazepam, or levetiracetam) should be continued at the same dose while starting Nootropil. Once clinical response is achieved, your doctor may attempt to reduce the doses of concomitant anti-myoclonic drugs if possible, to minimise polypharmacy.
Treatment with Nootropil should be continued for as long as the underlying condition requires. In patients with progressive myoclonic epilepsy or Unverricht-Lundborg disease, treatment should be continued throughout life. Every six months, your doctor should attempt a dose reduction or gradual withdrawal to determine whether symptoms have improved and the medication is still needed. Any dose reduction must be performed gradually, typically by 1.2 grams every two days, to prevent breakthrough myoclonus or seizures.
Adults – Cognitive Disorders (where licensed)
Dosage for Cognitive Symptoms in Elderly Patients
In countries where Nootropil is approved for age-related cognitive decline or cognitive symptoms of cerebrovascular disease, the typical daily dose is 2.4 to 4.8 grams per day, divided into two or three administrations. Using the 1200 mg tablets, this corresponds to two to four tablets daily.
The lower end of the dose range is often used as a starting dose, with gradual titration upward based on clinical response and tolerability. Therapeutic effect may take several weeks to become apparent, and treatment is typically continued for at least 8 to 12 weeks before assessing efficacy. Regulatory approval for this indication varies by country, and Nootropil is not approved for general cognitive enhancement in cognitively healthy individuals.
Children and Adolescents
Paediatric Use
In certain European countries, Nootropil is licensed as adjunctive therapy for dyslexia in children from 8 years of age, used alongside psychological and educational interventions. The typical paediatric dose is 3.2 grams per day, divided into two administrations (for example, 1.6 grams in the morning and 1.6 grams in the evening), which corresponds to 2 tablets (2400 mg) or 2.67 tablets of 1200 mg strength if available in different concentrations.
However, the 1200 mg tablet strength may be too large for some paediatric patients, and lower-strength formulations (such as 800 mg tablets or oral solution) are often preferred. The safety and efficacy of Nootropil for other indications in children and adolescents have not been established. Paediatric use must be carefully evaluated by a specialist physician and balanced against the potential benefits and risks for the individual child.
Elderly Patients
Geriatric Dosage Considerations
Elderly patients are more likely to have reduced renal function, which directly affects the elimination of piracetam. Dose adjustment based on estimated creatinine clearance is essential in patients aged 65 years and older. Regular monitoring of renal function is recommended during long-term treatment, typically every six months or as clinically indicated.
In addition to renal considerations, elderly patients may be more sensitive to central nervous system effects of piracetam, including nervousness, agitation, and sleep disturbances. A lower starting dose with cautious titration is generally advisable, and the medication should be reviewed periodically to confirm that it remains appropriate and beneficial.
Renal Impairment
Dose Adjustment in Reduced Kidney Function
Because approximately 80 to 100 percent of piracetam is eliminated unchanged by the kidneys, dose adjustment based on creatinine clearance (CrCl) is mandatory in patients with renal impairment:
- Mild impairment (CrCl 50–79 mL/min): Usual daily dose reduced by approximately one-third; divide into two or three doses
- Moderate impairment (CrCl 30–49 mL/min): Usual daily dose reduced to one-third; divide into two doses
- Severe impairment (CrCl 20–29 mL/min): Usual daily dose reduced to one-sixth; administer as a single daily dose
- End-stage renal disease (CrCl <20 mL/min or dialysis): Nootropil is contraindicated
Patients requiring haemodialysis have historically received a supplemental dose after each dialysis session in specialist settings, but routine use of Nootropil in dialysis patients is not recommended outside of specialist care. Your doctor will calculate the appropriate dose based on your most recent creatinine clearance measurement.
Missed Dose
If you forget to take a dose of Nootropil, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to compensate for the one you missed, as this may increase the risk of adverse effects without providing additional benefit.
For patients taking Nootropil for cortical myoclonus, maintaining consistent dosing is particularly important because missed doses may precipitate breakthrough myoclonic episodes or, in susceptible individuals, generalised seizures. If you have missed multiple doses, contact your doctor for guidance on how to safely resume treatment. Practical strategies to avoid missed doses include using a weekly pill organiser, setting alarms on your phone, or linking doses to regular daily activities such as meals or brushing your teeth.
Overdose
If you accidentally take more Nootropil tablets than prescribed, or if someone else takes your medication, contact your local poison control centre or go to the nearest emergency department immediately. Bring the medication packaging with you so that medical staff can identify the product and estimate the amount taken.
Piracetam has a very wide therapeutic index, and acute overdose rarely causes serious symptoms. The highest reported overdose has been approximately 75 grams, with no serious adverse effects identified. However, gastrointestinal symptoms such as nausea, diarrhoea with blood, and abdominal pain have been reported after ingestion of very large doses. Treatment is symptomatic and supportive; there is no specific antidote. Haemodialysis can remove piracetam from the body and may be considered in patients with severe overdose and significantly impaired renal function.
| Patient Group / Indication | Starting Dose | Maximum Dose | Notes |
|---|---|---|---|
| Adults – Cortical myoclonus | 7.2 g/day in 2–3 doses | 24 g/day | Titrate by 4.8 g every 3–4 days; attempt dose reduction every 6 months |
| Adults – Cognitive disorders | 2.4 g/day in 2–3 doses | 4.8 g/day | Where licensed; assess response after 8–12 weeks |
| Children 8+ – Dyslexia (adjunct) | 3.2 g/day in 2 doses | 3.2 g/day | Only with psychological/educational therapy; specialist supervision |
| Elderly (≥65 years) | Based on CrCl | Based on CrCl | Assess renal function every 6 months; lower starting dose preferred |
| Mild renal impairment (CrCl 50–79) | 2/3 of usual dose | 2/3 of usual maximum | Divide into 2–3 doses daily |
| Moderate renal impairment (CrCl 30–49) | 1/3 of usual dose | 1/3 of usual maximum | Divide into 2 doses daily |
| Severe renal impairment (CrCl 20–29) | 1/6 of usual dose | 1/6 of usual maximum | Administer as single daily dose |
| End-stage renal disease (CrCl <20) | Contraindicated | Contraindicated | Do not use |
| Hepatic impairment | Usual dose | Usual maximum | No dose adjustment typically required; piracetam is minimally metabolised by the liver |
What Are the Side Effects of Nootropil?
Like all medicines, Nootropil can cause side effects, although not everybody gets them. The most commonly reported side effects are nervousness, weight gain, hyperkinesia (increased motor activity), somnolence, depression, and asthenia. Most side effects are mild and transient, but serious effects require prompt medical attention.
Side effects are unwanted reactions that may occur during drug treatment. They are conventionally classified by frequency according to the Council for International Organizations of Medical Sciences (CIOMS) convention: very common (affects more than 1 in 10 people), common (affects 1 in 10 to 1 in 100 people), uncommon (affects 1 in 100 to 1 in 1,000 people), rare (affects 1 in 1,000 to 1 in 10,000 people), and very rare or not known (fewer than 1 in 10,000 people or unknown frequency from post-marketing surveillance).
Nootropil has been extensively studied for more than five decades and generally has a favourable safety profile compared to other neurological medications. The majority of side effects are mild, dose-related, and reversible upon dose reduction or discontinuation. However, some adverse effects may persist, worsen, or occasionally cause serious concern, particularly in elderly patients, those with impaired renal function, or those taking concomitant medications.
It is important to distinguish between side effects and allergic reactions. Side effects are typically predictable, dose-dependent pharmacological consequences, whereas allergic reactions are unpredictable immune responses that can occur at any dose. Signs of a serious allergic reaction include difficulty breathing, swelling of the face, lips, tongue or throat, severe skin rash or blistering, and rapid heartbeat. If you experience any of these symptoms, stop taking Nootropil immediately and seek emergency medical attention.
Many side effects improve as your body adjusts to the medication over the first few weeks of treatment. If any side effect persists, worsens, or causes significant discomfort, contact your healthcare provider. Your doctor may adjust your dose, recommend supportive measures, or consider alternative treatment options. You are strongly encouraged to report any suspected side effects to your national pharmacovigilance authority to help improve the safety information available for all patients.
Common Side Effects
May affect up to 1 in 10 people
- Nervousness or restlessness
- Hyperkinesia (increased motor activity or fidgeting)
- Weight gain
- Somnolence (drowsiness or sleepiness)
- Depression or low mood
- Asthenia (general weakness or fatigue)
Uncommon Side Effects
May affect up to 1 in 100 people
- Agitation, anxiety, or confusion
- Hallucinations (auditory or visual)
- Vertigo or dizziness
- Abdominal pain or upper abdominal discomfort
- Diarrhoea or nausea
- Vomiting
- Skin rash, pruritus (itching), or urticaria (hives)
- Angioedema (swelling of face, lips, or tongue)
- Insomnia or sleep disturbances
- Ataxia (loss of coordination) or loss of balance
- Worsening of existing epilepsy in predisposed patients
Rare and Very Rare Side Effects
May affect fewer than 1 in 1,000 people
- Bleeding tendencies (due to antiplatelet effect)
- Thrombophlebitis (inflammation of a vein with clot formation)
- Fever
- Hypertension (increased blood pressure)
- Hypotension (decreased blood pressure) with postural symptoms
- Peripheral oedema (swelling of hands or feet)
- Anaphylactoid reactions (rare severe allergic-type reactions)
- Hepatic reactions (rare reports of elevated liver enzymes)
- Severe cutaneous reactions (very rare)
- Libido alterations
Signs of a serious allergic reaction such as swelling of the face, lips, tongue, or throat; difficulty breathing or swallowing; severe skin rash with blistering; unexplained bruising or bleeding (including blood in stools, urine, or vomit, or unusually heavy menstrual bleeding); sudden severe headache; confusion or hallucinations; or a seizure. These symptoms require emergency medical care. Stop taking Nootropil and call your local emergency number or go to the nearest emergency department immediately.
Reporting Side Effects
If you experience any side effects, discuss them with your doctor or pharmacist. This includes any possible side effects not listed in the patient information leaflet. By reporting side effects you help provide more information on the safety of Nootropil and allow regulatory agencies to identify previously unknown adverse reactions. Most countries have established yellow card or similar pharmacovigilance reporting systems that accept direct reports from patients and healthcare professionals.
How Should You Store Nootropil?
Store Nootropil at room temperature below 25°C (77°F) in the original packaging to protect from light and moisture. Keep out of reach and sight of children. Do not use after the expiry date printed on the packaging. Return unused tablets to your pharmacy for safe disposal.
Proper storage is essential to maintain the quality, stability, and effectiveness of any medication. Nootropil film-coated tablets should be stored in a cool, dry place at a temperature not exceeding 25 degrees Celsius (77 degrees Fahrenheit). Avoid exposing the medication to excessive heat, direct sunlight, humidity, or freezing temperatures, as these conditions can affect the physical and chemical properties of the tablets and may reduce their therapeutic effectiveness.
Keep the tablets in their original packaging until you are ready to take them. The original blister pack or container is specifically designed to protect the medication from environmental factors such as light and moisture. If your Nootropil is supplied in blister packs, do not remove a tablet from its individual compartment until immediately before use. If the tablets are supplied in a bottle, keep the bottle tightly closed between uses to minimise exposure to humidity.
Always store Nootropil and all medications out of the reach and sight of children. Consider using a locked medicine cabinet or a storage location that small children cannot access. Child-resistant packaging is helpful but not childproof, and curious children may still attempt to open containers. Accidental ingestion of prescription medications by children is a medical emergency and should prompt immediate contact with a poison control centre or emergency services.
Check the expiry date regularly and do not use Nootropil after the date printed on the packaging. The expiry date refers to the last day of that month. Expired medications may have reduced potency or, in rare cases, may generate degradation products with potentially altered pharmacological activity. Avoid the temptation to use "old" supplies of medication, particularly for a condition as serious as cortical myoclonus where inadequate treatment may have clinical consequences.
Do not dispose of Nootropil via wastewater, household waste, or domestic recycling. Unused or expired tablets should be returned to your pharmacy for safe disposal. Many pharmacies, healthcare facilities, and community take-back programmes offer medication disposal services free of charge. Proper disposal protects the environment from pharmaceutical contamination of water supplies and prevents accidental exposure of children, pets, or others.
What Does Nootropil Contain?
Each Nootropil film-coated tablet contains 1200 mg of the active substance piracetam. In addition, the tablets contain inactive ingredients (excipients) that support the tablet's structure, stability, and film coating, including macrogol, magnesium stearate, and titanium dioxide-based coating components.
The active ingredient in each Nootropil film-coated tablet is piracetam 1200 mg. Piracetam (chemical name 2-oxo-1-pyrrolidine acetamide or 2-oxo-pyrrolidinyl-1-acetamide) is a cyclic derivative of gamma-aminobutyric acid (GABA) with the molecular formula C6H10N2O2 and a molecular weight of 142.16 g/mol. It is a white or almost white crystalline powder that is highly soluble in water, reflecting its excellent oral bioavailability of approximately 100%. The compound was first synthesised in 1964 at UCB Pharma in Belgium and has been in continuous clinical use in many countries for more than five decades.
In addition to the active ingredient, Nootropil tablets contain inactive ingredients (excipients) that perform various essential pharmaceutical functions such as binding the active ingredient into a cohesive tablet, ensuring appropriate tablet hardness and disintegration characteristics, providing a protective film coating, and giving the tablet its characteristic colour. Typical excipients found in Nootropil 1200 mg film-coated tablets include macrogol 6000, colloidal anhydrous silica, and magnesium stearate in the tablet core, with the film coating typically consisting of hypromellose (a cellulose derivative), macrogol 400 or similar polyethylene glycol, and titanium dioxide (E171) as an opacifying and colouring agent.
If you have known allergies or intolerances to any pharmaceutical excipients, discuss this with your doctor or pharmacist before starting Nootropil. Although reactions to excipients are uncommon, they can occur, and patients with multiple medication allergies may benefit from a careful review of all inactive ingredients in the specific formulation supplied to them. The complete and accurate list of excipients for the specific product you are prescribed is available in the patient information leaflet included inside the medication packaging.
The film coating on Nootropil tablets serves several important purposes in addition to colouring and aesthetic considerations. It protects the active ingredient from environmental factors such as moisture and oxygen, facilitates swallowing by providing a smooth surface, masks any inherent taste characteristics of the active ingredient, and may help prevent friability or breakage during packaging and handling. The film coating does not significantly affect the rate or extent of absorption of piracetam, which is rapidly and almost completely absorbed from the gastrointestinal tract regardless of formulation details.
Pharmaceutical Information
Nootropil 1200 mg film-coated tablets are typically presented as oblong white or off-white tablets with a score line on one side to facilitate breaking if needed, although the tablets should ideally be swallowed whole. The 1200 mg strength is particularly suitable for adult patients requiring large total daily doses, as fewer tablets are needed to achieve the target dose compared with lower strengths. For example, a patient requiring 9.6 grams per day takes only 8 tablets of 1200 mg, compared with 12 tablets at the 800 mg strength.
Other formulations of piracetam are available in different countries, including 800 mg film-coated tablets, 400 mg capsules, oral solutions (typically 33.3% or 20%), and solutions for intravenous or intramuscular injection (typically 200 mg/mL). The choice of formulation depends on the patient's dose requirements, ability to swallow solid dosage forms, and clinical circumstances. The intravenous formulation is primarily used in hospital settings for acute situations where rapid onset of action is needed or oral administration is impractical.
Frequently Asked Questions About Nootropil
Nootropil (piracetam) is prescribed primarily for the symptomatic treatment of cortical myoclonus in adults. In some countries it is also used as adjunctive therapy for cognitive impairment associated with cerebrovascular disorders and age-related cognitive decline. In several European countries it is licensed as an adjunctive treatment for dyslexia in children from 8 years of age, alongside standard psychological and educational interventions. The specific approved indications vary by country and regulatory jurisdiction. Always follow your prescribing physician's instructions regarding the specific indication for which Nootropil has been prescribed to you.
Take Nootropil exactly as prescribed by your doctor. The 1200 mg film-coated tablets are taken orally with a glass of water, with or without food. The daily dose is typically divided into two or three administrations spaced throughout the day (for example, morning, midday, and evening). For cortical myoclonus in adults, the usual starting dose is 7.2 grams per day (six 1200 mg tablets), divided into two or three doses, which can be gradually increased up to a maximum of 24 grams per day. Always follow the specific dosing instructions provided by your prescribing physician.
No, you should never stop taking Nootropil abruptly, particularly if you are being treated for cortical myoclonus. Sudden discontinuation may precipitate breakthrough myoclonic symptoms or generalised seizures in susceptible patients. If your doctor decides that Nootropil should be stopped, the dose should be reduced gradually – typically by 1.2 grams every two days – until the medication can be safely withdrawn. Never adjust the dose or discontinue treatment without consulting your prescribing physician first.
If you miss a dose of Nootropil, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and continue with your regular dosing schedule. Never take a double dose to make up for a forgotten dose. If you have missed multiple doses, contact your doctor for guidance. For patients with cortical myoclonus, consistent dosing is especially important because missed doses may precipitate breakthrough myoclonic episodes. Strategies such as using a pill organiser, setting phone alarms, or linking doses to regular daily activities can help prevent missed doses.
Yes, this is a clinically important interaction. Piracetam has antiplatelet properties and may potentiate the effects of anticoagulants such as warfarin, direct oral anticoagulants (DOACs), and antiplatelet drugs like aspirin or clopidogrel. The combination may increase the risk of bleeding. Clinical studies have shown that high doses of piracetam (9.6 grams per day) can prolong bleeding time, and Nootropil has been reported to increase prothrombin time when combined with warfarin. If you take blood thinners, your doctor may need to monitor your coagulation parameters more closely. Always inform your healthcare providers, surgeons, and dentists that you are taking Nootropil before any procedure.
The most commonly reported side effects of Nootropil are nervousness, hyperkinesia (increased motor activity), weight gain, somnolence, depression, and asthenia (general weakness). These effects are usually mild and transient, often improving as your body adjusts to the medication. Less common side effects include abdominal pain, nausea, skin rash, insomnia, and agitation. Serious but rare side effects include bleeding tendencies, allergic reactions, and, very rarely, liver enzyme abnormalities. Seek immediate medical attention if you experience signs of a serious allergic reaction (swelling of the face or throat, difficulty breathing, severe skin rash) or unexplained bruising or bleeding.
There are insufficient clinical data on the use of Nootropil in pregnant women. Animal studies have not shown direct or indirect harmful effects on pregnancy or foetal development, but as a precautionary measure, Nootropil should not be used during pregnancy unless clearly necessary and after careful evaluation of the benefits and risks. Women of childbearing potential should use effective contraception while taking Nootropil if pregnancy would be undesirable. Piracetam passes into breast milk, so breastfeeding is generally not recommended while taking Nootropil. If you are pregnant, planning pregnancy, or breastfeeding, discuss your treatment options with your doctor before starting or continuing Nootropil.
No. Piracetam (Nootropil) is not approved by the U.S. Food and Drug Administration for any medical indication and is not available as a prescription medicine in the United States. Despite this, Nootropil is approved in many European countries, the United Kingdom, parts of Asia, South America, and other regions for specific indications such as cortical myoclonus and certain cognitive disorders. The regulatory status varies significantly by country, reflecting differences in how regulatory agencies have evaluated the available clinical evidence. Marketing piracetam as a "cognitive enhancer" or nootropic supplement without a prescription is not endorsed by regulatory authorities and is not supported by robust clinical evidence in healthy individuals.
The onset of therapeutic effect with Nootropil depends on the indication being treated. In cortical myoclonus, improvement may be observed within days to weeks of reaching an effective dose, with gradual dose titration up to the individualised effective dose. For cognitive indications (where licensed), therapeutic effects typically develop more gradually, with at least 8 to 12 weeks of continuous treatment recommended before evaluating response. Because of this delayed onset, it is important to continue taking Nootropil as prescribed, even if you do not notice immediate benefit. If you feel that the medication is not working after an adequate trial, discuss this with your doctor rather than stopping treatment on your own.
Piracetam does not significantly alter blood alcohol levels, and there is no established acute interaction between Nootropil and moderate alcohol consumption. However, alcohol itself can worsen neurological symptoms, impair cognitive function, and interact with many other medications you may be taking. If you are being treated for cortical myoclonus or a neurological condition, your doctor may advise limiting or avoiding alcohol. Moderate alcohol consumption is generally considered acceptable for most patients on Nootropil, but individual advice from your healthcare provider is recommended, particularly if you take other medications or have coexisting medical conditions.
References and Sources
This article is based on internationally recognised medical and pharmaceutical guidelines, regulatory documents, and peer-reviewed clinical literature. All information has been reviewed by qualified healthcare professionals following evidence-based principles and the GRADE framework.
- European Medicines Agency (EMA). Summary of Product Characteristics: Piracetam-containing medicinal products – Article 31 referral. EMA/CHMP, 2010–2024. Available at: www.ema.europa.eu
- Winblad B. Piracetam: A Review of Pharmacological Properties and Clinical Uses. CNS Drug Reviews. 2005;11(2):169–182. doi:10.1111/j.1527-3458.2005.tb00268.x
- Malykh AG, Sadaie MR. Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders. Drugs. 2010;70(3):287–312. doi:10.2165/11319230-000000000-00000
- Flicker L, Grimley Evans G. Piracetam for dementia or cognitive impairment. Cochrane Database of Systematic Reviews. 2001, Issue 2. Art. No.: CD001011. doi:10.1002/14651858.CD001011
- Koskiniemi M, Van Vleymen B, Hakamies L, Lamusuo S, Taalas J. Piracetam relieves symptoms in progressive myoclonus epilepsy: a multicentre, randomised, double blind, crossover study comparing the efficacy and safety of three dosages of oral piracetam with placebo. Journal of Neurology, Neurosurgery & Psychiatry. 1998;64(3):344–348.
- Brown P, Steiger MJ, Thompson PD, et al. Effectiveness of piracetam in cortical myoclonus. Movement Disorders. 1993;8(1):63–68. doi:10.1002/mds.870080112
- Fedi M, Reutens D, Dubeau F, Andermann E, D'Agostino D, Andermann F. Long-term efficacy and safety of piracetam in the treatment of progressive myoclonus epilepsy. Archives of Neurology. 2001;58(5):781–786.
- British National Formulary (BNF). Piracetam: Prescribing Information, Indications, Dose and Contra-indications. NICE / BMJ Publishing Group, 2024. Available at: bnf.nice.org.uk
- World Health Organization (WHO). WHO Collaborating Centre for Drug Statistics Methodology: ATC/DDD Index – N06BX03 Piracetam. Oslo: WHO, 2024. Available at: www.whocc.no
- Giurgea C. Vers une pharmacologie de l'activité intégrative du cerveau. Tentative du concept nootrope en psychopharmacologie. Actualités Pharmacologiques. 1972;25:115–156.
- Stockley IH, Baxter K (eds). Stockley's Drug Interactions. 12th Edition. Pharmaceutical Press, 2023.
- Goodman & Gilman's. The Pharmacological Basis of Therapeutics. 14th Edition. McGraw-Hill Education, 2023.
- European Pharmacopoeia Commission. European Pharmacopoeia, 11th Edition: Piracetam Monograph. Council of Europe, 2023.
- Müller WE, Eckert GP, Eckert A. Piracetam: novelty in a unique mode of action. Pharmacopsychiatry. 1999;32(Suppl 1):2–9.
About the Medical Editorial Team
This article has been written and reviewed by iMedic's Medical Editorial Team, consisting of licensed physicians and specialists in clinical pharmacology and neurology with expertise in nootropic agents, movement disorders, drug safety, pharmacovigilance, and evidence-based medicine.
iMedic Medical Editorial Team – specialists in clinical pharmacology and drug information. All content is researched and written using peer-reviewed sources, international pharmaceutical guidelines (EMA SmPC, BNF, WHO), and regulatory documents from multiple jurisdictions.
iMedic Medical Review Board – independent panel of qualified physicians including specialists in neurology and clinical pharmacology who review all drug information content for accuracy, completeness, and clinical relevance according to EMA, FDA, and WHO standards.
Editorial Standards: All pharmaceutical content on iMedic follows strict editorial standards based on the GRADE evidence framework. We do not accept any form of pharmaceutical industry sponsorship or advertising. Our content is independent, evidence-based, and written for patients and caregivers. Read more about our editorial standards.